Carbamazepine Tablets USP, 200 mg have an estimated market size of $32 million for 12 months ending December 2024, according ...

The life sciences innovation ecosystem continued to evolve and expand in 2024 as the industry continued to adapt to a complex and dynamic range of geopolitical, technological and social uncertainties.

Alembic Pharmaceuticals receives USFDA approval to market Carbamazepine tablets (200mg) in the US. The generic drug is ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Alembic Pharmaceuticals Limited on April 17, 2025, informed that it has received final approval from the US Food & Drug ...

Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP ...

Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Carbamazepine Tablets USP, ...

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

The Healthcare Analytics Market is expected to expand at a CAGR of ~20% during the forecast period. Key factors driving this ...

At the same time, drugmakers have come to rely on the U.S. market for the bulk of their revenue. In 2022, the U.S. accounted ...

US tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...